Clinical Trials | February 17, 2026
Alto Neuroscience completes enrollment in Phase 2 trial for first-of-its-kind schizophrenia cognitive treatment
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Alto met its enrollment goal with 83 patients across 13 US clinical sites
New study presents a human-relevant stress model for assessing potential therapeutics
The cognitively operated system is a mother patent invention, first launched in India
Adya Anubhuti launches ADHD Copilot, an AI-powered platform designed to reduce stress and mental overload
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
Subscribe To Our Newsletter & Stay Updated
